1) Global Burden of Disease Cancer Collaboration; Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, et al: Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study. JAMA Oncol 3: 524-548, 2017.
2) Shield KD, Ferlay J, Jemal A, Sankaranarayanan R, Chaturvedi AK, et al: The global incidence of lip, oral cavity, and pharyngeal cancers by subsitein 2012. CA. Cancer J Clin 67: 51-64, 2017.
3) Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, et al: Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 375: 1856-1867, 2016.
4) Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, et al: Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol 81: 45-51, 2018.
5) Subramaniam SS, Paterson C, McCaul JA: Immunotherapy in the management of squamous cell carcinoma of the head and neck. Br J Oral Maxillofac Surg 57: 957-966, 2019.